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I LITERATURE SECTION 
 
1. Introduction 
 
1.1 ADP-ribosylation 
 
Post-translational modifications (PTMs) play a crucial role in various mechanisms of cellular 
proliferation. Some of the PTMs can be divided to poly-ADP-ribosylation (PARylation) and 
mono-ADP-ribosylation (MARylation). The proteins that perform such PTMs are called poly-
ADP-ribose polymerases (PARPs), also known as diphtheria toxin –like ADP-ribosyl 
transferases (ARTDs). As name indicates, MARylating PARP/ARTD-family proteins add only 
an ADP-ribose monomer, whereas PARylating PARP/ARTD-family proteins add a chain of 
ADP-ribose polymer to target proteins. PARylation and MARylation are important during 
several biological processes, such as gene transcription, stress response, heat shock for instance, 
response to unfolded protein, and deoxyribonucleic acid (DNA) damage response (DDR). 
(Flohr et al., 2003; Siegel & McCullough, 2011; Vyas et al., 2013; Liu & Yu, 2015) 
The family of PARPs can be divided to 17 differently functioning proteins. This group can be 
divided to tankyrases, zinc-finger-, DNA-dependent- and unclassified PARPs. The 
PARylation/MARylation process itself requires ADP-ribose to function, as its name implicates, 
and it is acquired from nicotinamide adenine dinucleotide (NAD+) by PARP/ARTD–family 
proteins. Furthermore, the ADP-ribosylation is required in DNA repair mechanisms. (Flohr et 
al., 2003; Liu & Yu, 2015) 
Not only are PARPs required for DNA repair mechanisms, but they can also commence non-
caspase coordinated apoptosis. One example of such an event is an insurmountable cell stress, 
namely elevated oxygen radical levels continuously damaging DNA. In these types of DNA 
damaging events PAR is excessively formed, namely via PARP1 activity, leading to apoptosis 
inducing factor (AIF) release from mitochondria. Furthermore, the released AIF translocates 
into nucleus and induces apoptosis via chromatin condensation and DNA cleavage into 50 
kilobase (kb) fragments. (Siegel & McCullough, 2011) 
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DNA damage is linked to cancer, and the ARTDs play a role in breast cancer, which is one of 
the most severe cancer in women. In some cases, this disease arises from two gene mutations 
in BRCA1 and BRCA2. The inhibition of ARTDs with PARP inhibitors (PARPi), especially 
ARTD1, are noted to lead especially specific cell killing (Tutt et al., 2010). Not only the PARPi 
has the potential to sensitize the cells to the DNA damage, but also the inhibitors can protect 
the cells from necrosis. One such PARPi preserving the cells is 3-aminobenzamide, which has 
been proven to decrease the follicular cell necrosis levels (Makogon et al., 2010). 
ARTDs has also a dual nature, both preserving and damaging cells, depending on the energy 
availability. If only a little of energy source (NAD+ and ATP) is present, the ARTD activity 
lead to necrosis. In the other hand, if energy is available, DNA repairing enzymes are activated 
via ARTD, and thus the cells proliferate. (Putt & Hergenrother, 2004) 
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2. Review of the literature 
 
2.1 Mono-ADP-ribosylation 
 
A post-translational modification (PTM) is an event, which covers a series of covalent amino-
acid side chain modifications. To date, 300 PTMs has been approximated to occur, and one of 
such events is called ADP-ribosylation. (Kumar & Prabhakar, 2008) 
ADP-ribosyltransferases (ARTs) ADP ribosylate their target proteins. This PTM occurs during 
various regulation processes, including stress response, apoptosis, DNA damage repair and cell 
division. Also, it divides into mono-ADP-ribosylation (MARylation) and poly-ADP-
ribosylaion (PARylation). (Bütepage et al., 2015; Munnur & Ahel, 2017) 
In a chemical level, ARTs use NAD+ as a substrate for branching ADP ribose, with 
nicotinamide releasing as derivative. If there are no proteins to be ADP-ribosylated, free amino 
acids are capable to act as substrates. If no free amino acids are present, the NAD+ is slowly 
hydrolyzed to ADP ribose and nicotinamide. On figure 1, the ADP-ribosylation is represented. 
(Han et al., 1996; Berti et al., 1997; Bütepage et al., 2015) 
 
 
 
 
 
Figure 1: An overview of ADP-ribosylation. On this schematic, β-NAD+ is utilized into ADP-
ribose via ARTD activity. 
 
ARTs target their ADP-ribosylation on several amino-acids. Most common targets are aspartate 
(Asp), glutamate (Glu), and serine (Ser). Other residues to be ADP-ribosylated are arginine 
(Arg), cysteine (Cys) and lysine (Lys). One of the target proteins undergoing the ADP-
ribosylation are histones. Upon DNA damage, PARP-family proteins target histones, namely 
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ARTD1 and ARTD2, from which ARTD1 targets primarily histone H1 (linker histone), and 
ARTD2 targets core histones, such as H2B. The ADP-ribosylation of histones cause the 
chromatin structure relaxation, facilitating the single-strand break repair/base excision repair 
(SSBR/BER) factors to the DNA damage site. However, it is unclear which specific site of the 
histones become PARylated. (Herceg & Murr, 2011; Feijs et al., 2013; Leidecker et al., 2016; 
Rakhimova et al., 2017; Bartlett et al., 2018) 
On table I, a list of PARP-family proteins with ARTD-name and suggested activity type is 
represented. (Vyas et al., 2014; Yang et al., 2017) 
 
Table I: A list of ARTDs. 
PARP ARTD Activity 
PARP1/PARP ARTD1 PAR 
PARP2 ARTD2 PAR 
PARP3 ARTD3 MAR 
PARP4/vPARP ARTD4 MAR 
TNKS1 ARTD5 PAR 
TNKS2 ARTD6 PAR 
PARP6 ARTD17 MAR 
PARP7/tiPARP ARTD14 MAR 
PARP8 ARTD16 MAR 
PARP9/BAL1 ARTD9 MAR 
PARP10 ARTD10 MAR 
PARP11 ARTD11 MAR 
PARP12 ARTD12 MAR 
PARP13/ZC3HAV1 ARTD13 Inactive 
PARP14/BAL2 ARTD8 MAR 
PARP15/BAL3 ARTD7 MAR 
PARP16 ARTD15 MAR 
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2.2 PARP10/ARTD10 
 
Poly-ADP-Ribose Polymerase 10 (PARP10), or Diphtheria Toxin –like ADP-
ribosyltransferase (ARTD10), is expressed in all tissues, and it interacts with at least 8000 
proteins. In humans, ARTD10 interferes with activities of various cellular proteins via 
MARylation. Few examples of the target proteins of ARTD10 are growth factors, receptors and 
different kinases. The PTM of these proteins makes regular cell proliferation possible. 
However, it has been noticed that inhibition of overexpressed ARTD10 aid cells to proliferate. 
(Feijs et al., 2013; Nicolae et al., 2014; Bütepage et al., 2015; Ekblad et al., 2015; Venkannagari 
et al., 2016) 
Generally, the modification by ARTD10 leads to an inhibition of protein activity in a cellular 
signaling pathways. One of such pathways is a nuclear factor-kappa B essential modulator 
(NEMO) pathway, which require K63-pUb to be activated. ARTD10 can prevent the activation 
of this pathway via binding to K63-pUb with its two ubiquitin-interaction motifs (UIMs). 
(Verheugd et al., 2013; Bütepage et al., 2015) 
ARTD10 is suggested to act as an oncogene, promoting the tumor growth. Also, loss of this 
enzyme has been noted to reduce cancer cell proliferation, thus the inhibition of ARTD10 is a 
promising method of anti-cancer therapy. (Schleicher et al., 2018) 
 
2.2.1 Structure of ARTD10 
 
ARTD10 consists of various regions, which all have important roles in cellular processes. It has 
a region containing motif designed to recognize RNA, an RNA recognition motif (RRM, amino 
acids (aa) 11-85). This motif has various regulation targets amongst different RNA sequences, 
and it occurs via group of specified RNA binding proteins (RBPs). Other regions ARTD10 
consists of are glycine-rich region (Gly, aa 281-399) , nuclear uptake mediating conserved 
nuclear targeting region (aa 435-528), glutamine-rich region (Glu, aa 588-697) including 
Nuclear Export Sequence (NES, aa 598-607), which is suggested to have a role in nuclear 
localization, and two Ubiquitin-Interacting-Motifs (UIMs, aa 650-667 and 673-690), which 
attach to ubiquitinated molecules such as proliferating cell nuclear antigen (PCNA) upon 
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replication fork stalls. The distinguishable catalytic domain (aa 818-1013) and PCNA-
interacting peptide (PIP-box, aa 834-841) box of ARTD10 are located at C-terminus. This 
domain is region in which MARylation of target proteins occur. On figure 2, an overview of 
ARTD10 structure is represented. (Yu et al., 2005; Kleine et al., 2008; Yu et al., 2011; Herzog 
et al., 2013; Verheugd et al., 2013; Nicolae et al., 2014; Bock et al., 2015; Schleicher et al., 
2018).  
 
 
 
Figure 2: An overview of ARTD10. On this graphical representation, different regions of full-
length human ARTD10, a 1025 amino acids long protein, can be seen. 
 
2.2.2 ARTD10 response to DNA damage 
 
DNA is exposed constantly to exo- and endogenous damages. To maintain regular activity of 
cells, a variety of DNA repair mechanisms must act correctly. If repair mechanisms are unable 
to treat DNA properly, several different genomic anomalies will occur, namely chromosomal 
translocations, gain or loss of entire chromosomes, and point mutations. Furthermore, if 
multiple repair mechanisms of DNA become altered, a tumorigenesis will occur due to 
unsuccessful DNA damage repairing. (Mouw et al., 2017) 
One of the ARTD10 properties is to translocate between compartments of cytoplasm and 
nucleus, but it is not completely clear how its translocation occurs. Kleine H. and colleagues 
(2012) has discovered that the nuclear ARTD10 potentially interacts with myelocytomatosis 
viral oncogene homolog (MYC) and the shuttling is mediated with NES region binding 
chromosome region maintenance 1 (CRM1) -dependent nuclear export sequence and a central 
nuclear localization promoting sequence of ARTD10. However, the nuclear localization region 
of ARTD10 does not provide full nuclear translocation. ARTD10 is distributed equally between 
nuclear compartments and cytoplasm, and it is suggested the co-localization between cytoplasm 
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and nucleus occurs with p62/SQSTM1, a pUb receptor. (Kleine et al., 2012; Herzog et al., 
2013) 
A phenomenon called DNA damage response (DDR) alters the chromatin structure. This affects 
epigenetic marks as well as essential chromatin factors, with crucial connections for functions 
of epigenome. The chromatin goes through a tense spatio-temporal regulation. It has been 
noticed that the chromatin relaxation occurs at DNA break sites, followed by temporary 
compaction. (Nicolae et al., 2014; Dabin et al., 2016) 
One of the consequences of DNA damages are DNA lesions. If DNA lesions remain unrepaired, 
the DNA will eventually break. The known mechanisms responding to DNA damage include 
nucleotide excision repair (NER), translesion synthesis (TLS), base excision repair, mismatch 
repair. ARTD10 have been identified to act as a component of TLS mechanism. ARTD10 is 
actively taking part in these repair mechanisms during S-phase, and it have been noted the cells 
lacking ARTD10 are uncapable to restart DNA replication after DNA damage specified to S-
phase. (Nicolae et al., 2014; Shahrour et al., 2016) 
A ring-like PCNA is a polymerase δ cofactor, and it surrounds the DNA strand during synthesis 
recruiting DNA repair- and replicator proteins (Peterson & Kovyrshina, 2019). Upon DNA 
damaging events, one of the recruited proteins is ARTD10, which is recruited via its exclusive 
PIP-box. It is shown before that ARTD10 can bind to PCNA with either PIP-box or UIMs, 
which binds to ubiquitinated PCNA. Also, the binding with UIMs and PIP-box occurs 
respectively. Nicolae and colleagues suggest the genomic stability is promoted via recruitment 
of ARTD10 to replication fork stalls, speculating this activity might have a role in DNA repair. 
The recruitment is vital, since DNA anomalies, such as repetitive elements, lesions, secondary 
structures and further non-canonical structures, will eventually seize the progression of DNA 
polymerases. The replication fork arrest leads to PCNA mono-ubiquitination at Lys164. The 
ubiquitination will eventually promote recruitment of UIM –and PIP-box possessing TLS 
polymerases, culminating to stalled fork restart (Nicolae et al., 2014; Schleicher et al., 2018). 
The overexpression of ARTD10 have been identified in a broad spectrum of tumors, and thus 
it might have a role as an oncogene in transformation promotion. However, when 
overexpressed, ARTD10 is known to induce apoptosis in HeLa-cells. Schleicher and colleagues 
(2018) noted the overexpression of ARTD10 led to enhanced growth of RPE-1 -cells, and the 
overexpression of catalytic domain did not have effect on cellular proliferation. In the contrast, 
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the downregulation of ARTD10 is known to result into various neurodegenerative disorders 
such as Cockayne syndrome, PCNA mutation, xeroderma pigmentosum, and ataxia 
telangiectasia. Shahrour and colleagues (2016) discovered a neurodegenerative disease via 
ARTD10 deficiency, which led to increased apoptosis levels due flawed DNA repair 
mechanism (Herzog et al., 2013; Shahrour et al., 2016; Schleicher et al., 2018). 
 
2.3 ARTDs in DNA damage response 
 
A common feature of ARTD-family proteins is the ADP-ribosylation, which is suggested to 
have a role during dsDNA damage repair, such as single-strand breaks (SSBs). As a part of 
DNA repair mechanism, ARTDs are targeting histones H3 and H4 upon DNA stress. As an 
example, histone H3 is removed from DNA damage site due PARylation, granting DNA repair 
space. Once histones H3 and H4 are PARylated, the acetylation levels of the tails are increased. 
Thus, it is suggested that PARylation allows constitutive transcription maintenance due 
preventing histone deacetylation. However, if amount of poly(ADP-ribose) is either extensive 
or restricted, histones become hypoacetylated. (Flohr et al., 2003; Verdone et al., 2015; Chen 
et al., 2018) 
 
2.3.1 Activity on DNA damage sites 
 
In a summary, ARTD-dependent pathways of DNA damage repair activity can be divided in 
three different categories, which are DNA damage detection, PAR-dependent repair factor 
recruitment, and PAR-dependent biochemical activity regulation. Upon SSBs, ARTDs binds to 
specific ends via zinc finger domains. These domains bind mutually, instead of competing for 
the same binding site. Furthermore, ARTD binds to a damaged DNA site as a monomer, and 
the positioning of heavily modified ARTD region, consisting of linker residues that subsequent 
BRCA1 C terminus (BRCT) fold, is dependent on domain organization. Finally, the allosteric 
activation of ARTD requires reorganization of the helical HD domain. The HD blocks the 
catalytic domain from NAD+ binding, and the deletion of HD renders ARTD1, ARTD2, and 
ARTD3 active. These proteins are activated upon different DNA damage, ARTD2 and ARTD3 
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being activated most in the cases upon 5´ terminal DNA phosphorylation and SSBs whereas 
ARTD1 is activated mostly upon double-strand breaks (DSBs). Also, ARTD1 assembles on 
DNA via PAR-mediated automodification, which lead eventually ARTD1 to unbind DNA 
whilst decreasing catalytic output. However, the ratio between ARTD1 mediated repair factor 
recruiting and ARTD1 unbinding automodifications is not clear. The complex of DNA 
repairing factors relies to a sophisticated network consisting of protein-protein and protein-
DNA contacts. One such an interaction is histone PARylation factor 1 (HPF1), which is 
identified as an ARTD1 binding counterpart, regulating the catalytic output. (Trucco et al., 
1998; D’Amours et al., 1999; Sukhanova et al., 2005; Langelier et al., 2012; Dawicki-McKenna 
et al., 2015; Eustermann et al., 2015; Gagné et al., 2015; Gibbs-Seymour et al., 2016; Liu et 
al., 2017) 
 
2.4 PARP inhibitors in DNA damage 
 
PARPi possesses promising clinic anti-cancer activity. The effect relies on DNA repair 
mechanism inhibition and thus enhance the effects of anti-cancer therapy, namely 
topoisomerase I poisons, ionizing radiation (IR) and DNA methylating agents. These damages 
are enhanced, since the ARTD inhibition reduces poly(ADP-ribose) (PAR) chain synthesis and 
thus, seizes additional repair factor recruitment. (Gavande N. S. et al., 2016) 
A few examples of hypersensitization are the cells possessing imperfect DNA mismatch repair 
(MMR), homologous replication repair (HRR) mechanism, or lacking ARTDs. This makes 
treatment of tumors emerged from breast cancer gene (BRCA) mutation carrying cells effective, 
since the PARP1- and PARP2 inhibitors kills HRR imperfect cells via synthetic lethality 
between PARPi and defects in HRR mechanism. (Curtin & Szabo, 2013; Morgan et al., 2015; 
Gavande et al., 2016; Bian et al., 2019). 
 
2.4.1 PARP inhibitors 
 
Once the ARTDs were discovered, PARPi have been developed to bind specifically in active 
sites of ARTDs, such as NAD+ binding site. The modern PARPi are NAD+ competitors, 
10 
 
occupying catalytic pockets of ARTDs. Examples of such PARPi are Olaparib (AZD-2281), 
rucaparib, veliparib, niraparib and talazoparib, which are ARTD1, ARTD2- and ARTD3 
inhibitors. These inhibitors inhibit the enzymatic activity, including automodification, and trap 
the enzyme to DNA strand. The overall effect on cells are arrest of cell cycle, especially at 
G2/M checkpoint, and the cells are known to be radiosensitive during this phase. Also, these 
chemicals enhance the potency of DNA-damaging agents such as cisplatin (Curtin & Szabo, 
2013; Gavande et al., 2016; Dockery et al., 2017; Prasad et al., 2017; Bian et al., 2019; Camero 
et al., 2019). 
 
2.4.2 Mono-ARTD inhibitors 
 
The inhibitors targeting mono-ARTDs (mARTDs) are gathering more interest for their 
advantageous properties, as mARTDs are now known to take part in several cellular processes. 
As a common feature with other PARPi, mARTD inhibitors so far possess a nicotinamide-
mimicking characteristic, competing with substrate NAD+ and preventing the enzymatic 
activity. However, challenges in developing the mARTD inhibitors lies on selectivity as well 
as potency exists, and more efforts to discover specific compounds are needed. Catalytic 
domain is highly conserved in ARTD family proteins and therefore compounds often inhibit 
multiple enzymes. At a moment, research groups are at an early-hit development phase, such 
as research groups of Schuller (2017), Holechek (2018), and Morgan (2019), primary seeking 
appropriate ARTD8 inhibitor, and due this fresh frontier of PARPi studies, there is not yet data 
from clinical trials. At a moment, one example of specific mARTD inhibitor is OUL35, which 
inhibits specifically ARTD10. (Ekblad et al., 2015; Venkannagari et al., 2016; Schuller et al., 
2017; Holechek et al., 2018; Morgan et al., 2019) 
 
2.4.2.2 OUL35 
 
OUL35 (4-(4-carbamoylphenoxy)benzamide, (NSC39047)), is a recently discovered inhibitor 
of ARTD10, by Lehtiö group. By docking studies, it was found that OUL35 binds same way as 
3AB, a small general ARTD inhibitor, by binding in the NAD+ binding pocket. They also noted 
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that the OUL35 -treated ARTD10-overexpressing HeLa cells were rescued from ARTD10-
induced apoptosis. (Venkannagari et al., 2016)  
On figure 3, structures of Olaparib and OUL35 is shown. The NAD+ mimicking regions are 
highlighted with transparent gray circles. As recognizable differences, Olaparib is extending 
towards the adenosine-binding pocket along NAD+ binding branch, whereas the benzamide 
motif of OUL35 is extending towards the acceptor from the NAD+ binding pocket. (Dawicki-
McKenna et al., 2015; Venkannagari et al., 2016) 
 
 
 
 
 
 
 
Figure 3: A comparison between Olaparib and OUL35. 
 
2.5 DNA damaging chemotherapeutics 
 
DNA can be damaged by many means, both exo- and endogenous. Exogenous damage is 
broadly used in radiation therapy and chemotherapy, which lead to various DSBs, SSBs, base 
damages and termini modifications. The key aspect of chemotherapy is to use synergetic 
compounds together to provide most effective cancer-eradication, and to extend the 
effectiveness of treatment even more, simultaneous repair mechanism inhibition can be used. 
The compounds modifying specifically DNA bases chemically dates to 1960s and 1970s. 
During those days, one of the most efficacious anti-cancer drugs, platinum agents bearing 
alkylating-like properties, were found, and amongst the found compounds, cisplatin is one of 
the most successful one. The chemotherapy treatment is utilized broadly amongst various 
cancer types alongside surgical procedures, attempting to effectively eradicate cancer. The 
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previously mentioned cisplatin is effective to a certain extent, but it generates severe side-
effects to the patients, namely nephro- neuro- and hepatotoxicity. Moreover, the cancer cells 
either possesses or develops resistance to this compound. Thus, it is important to develop 
different drug combinations, and cisplatin has been developed furthermore ever since into 
thousands of different analogs. The combination chemotherapy has requirements itself as well, 
namely enhancing the cancer cell kill effectiveness, non-overlying toxicity and cancer 
resistance avoidance, since if the tumor develops a resistance to a drug, reoccurrence of disease 
will be a matter of time. Also, the importance of ARTDs should not be ignored. It is known that 
in regular cellular conditions, when enough energy is stored, PARPi prevent the ARTD-
mediated DNA repairing protein recruitment. Nicolae and colleagues (2014) suggest that the 
cells may utilize ARTD10 to decrease the effects of DNA-damaging chemotherapeutics, and 
thus preventing the full effect of anticancer drugs. Nevertheless, the chemotoxicity resistance 
based on ARTD10 activity can be prevented with target-specific inhibitors, which are 
constantly being studied and developed. (Putt & Hergenrother, 2004; Bruijnincx & Sadler, 
2008; Cheung-Ong et al., 2013; Nicolae et al., 2014; Gavande et al., 2016; Hu et al., 2016) 
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II EXPERIMENTAL PART 
 
3. Aim of the project 
 
The key aspects of this projects were 
1) to express and purify recombinant full length ARTD10, 
2) to conduct IC50 experiments on ARTD10 to compare values between full length protein and 
catalytic fragment used previously, 
3) to determine the effects of DNA damaging agents as well as OUL35 on ARTD10 levels and 
localization in cells, and 
4) to determine whether the OUL35 increases the effects of DNA damaging agents on breast 
cancer cells and whether there is correlation with ARTD10 expression levels 
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4. Materials and methods 
 
4.1 Protein expression 
 
The ARTD10 expressing plasmid was transformed previously to bacteria, which was inoculated 
from glycerol stocks of frozen E. coli Rosetta 2 (DE3) –cells. The strain possessed the ARTD10 
encoding sequence in pNIC-Bsa4 –plasmid with poly-his tag and tobacco etch virus (TEV) 
protease recognition sequence. Preliminary culture used consisted of 5 ml of LB broth 
(Lysogeny Broth; 25% LB broth Miller, dH2O). The antibiotics were kanamycin (50 µg/ml) 
and chloramphenicol (37 µg/ml), and the cells were incubated overnight in +37°C shaking 
incubator. 
The overnight culture was inoculated into secondary culture of autoclaved auto-induction 
medium (AIM; 5% Formedium Auto Induction Terrific Broth), and the cells were incubated in 
a 5 l Erlenmeyer flask, with final volume of 750 ml, at shaking +37 °C incubator. With two-
hour intervals, OD600 value was checked with spectrophotometer. Once the OD600 reached 
1.0, incubator temperature was lowered to +18 °C, and let the cells grow overnight (16h). 
After 16 h incubation, the cells were spun down with 4200 rpm (Beckman J6-MI Centrifuge, 
JS-42 rotor, Beckman tubes) for 30 minutes (+4 °C). After centrifuging, pellets were weighed, 
and lysis buffer was added (1.5 ml/g pellet) (50 mM HEPES, 500 mM NaCl, 10% glycerol, 10 
mM imidazole, 0.5 mM TCEP, pH 7.8). The cells were lysed using cell disruptor with pressure 
of 20 kpsi (Constant Systems Ltd). Two passes were required to successfully lyse the cells. 
 
4.2 Protein purification 
 
The used methods for ARTD10 were immobilized metal ion affinity chromatography (IMAC), 
anion-exchange chromatography (AEC) and finally, size-exclusion chromatography (SEC). 
Before initiating the IMAC purification, the lysate was filtered using 0.45 µM filter (Sartorius). 
Centricon (30 kDa) was used to obtain appropriate protein solution volume after IMAC. 
Furthermore, sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
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used to check the purity level of eluate obtained from chromatography, and as a standard, 
Precision Plus Protein All Blue Standards (BioRad, 250-10 kDa) was used. 
IMAC is based most commonly on poly-histidine (poly-his) -tail protein affinity to a metal ion 
saturated column, in the case of this work, nickel. The cells are firstly lysed with, for example, 
cell disruptor and the obtained lysate is filtered. Once the lysate is filtered from cell debris, it is 
passed through an IMAC column. The following steps consists of column washes using 
washing buffers with different concentrations of imidazole. Elution Buffer has the highest 
concentration of imidazole, rinsing away almost everything off the column. The imidazole 
competes with histidine in binding to nickel, resulting poly-his -and other nickel-binding 
proteins rinse away. 
IMAC column used for purification was pre-packed high-performance (HP) IMAC column (GE 
healthcare). The used washing buffers were Wash 1 (30 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 350 mM NaCl, 10 mM Imidazole, 10% glycerol, 0,5 
mM Tris(2-carboxyethyl)phosphine (TCEP), pH 7.5), Wash 2 (30 mM HEPES, 350 mM NaCl, 
25 mM Imidazole, 10% glycerol, 0.5 mM TCEP, pH 7.5) and Elution Buffer (30 mM HEPES, 
350 mM NaCl, 350 mM Imidazole, 10% glycerol, 0.5 mM TCEP, pH 7.5). 
If protein of interest interacts with nucleic acids, one can remove the contaminating RNA or 
DNA with heparin chromatography. This was made with buffer A (25 mM Tris, 50 mM NaCl, 
pH 7.6), and the column of this purification step was HiTrap Heparin HP column (GE 
healthcare). 
The matrix of AEC consists of beads of cross-linked agarose having strong anion-exchange 
properties. The charge is dependent on potential of hydrogen (pH) value (effects on isoelectric 
point (pI) as well), and the oppositely charged molecules attracts each other resulting protein 
binding on column. The protein is washed away as fractions with buffers, Buffer A and Buffer 
B typically, due charge changes of the column by change of sodium chloride (NaCl) gradient. 
The column used for AEC was Q-sepharose and the buffers used for elution were Buffer A (25 
mM Tris, 50 mM NaCl, pH 7.6) and Buffer B (25 mM Tris, 1 M NaCl, pH 7.6). 
The molecules passed through SEC column do not bind to the medium, but the proteins are 
separated according to the size. The larger the protein, the faster it passes through the column. 
The proteins are eluted from the column with Gel Filtration Buffer (30 mM HEPES, 350 mM 
NaCl, 10% glycerol, 0.5 mM TCEP, pH 7.5) and the wanted protein is collected in different 
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fractions. In case of full-length PARP10, S200 column was used (Superdex, resolve (Mr) from 
10 000 to 600 000) with matrix consisting of a cross-linked spherical composite of dextran and 
agarose. 
 
4.3 Activity assay and inhibitory potency measurements 
 
A fluorescence-based activity assay was performed to seek the appropriate concentration of 
inhibitor, OUL35, to complete ARTD10 inhibition, using serine-rich protein-specific kinase 2 
(SRPK2) as a substrate. The assay was made in 96-well plates (Venkannagari et al., 2013). On 
table II, the layout of the contents is represented. 
 
Table II: Layout of half maximal inhibitory concentration (IC50). Well column 1 has 50 µl 
50 mM Tris buffer as a blank, column 2 acts as a negative control and column 12 is a positive 
control. Wells 3-11 separates into two parts, having upper 4 wells as a control’s wells without 
PARP10. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
            
  25 µl  
 25 µl 1 µM NAD+ 25 µl 
B 
 1 µM 
NAD 
 1 µM NAD+ 
  10 µl  
  50 mM Tris  
C 
    
  10 µl  
50 mM 
Tris 
5 µl 2 µM SRPK2 10 µl 
D 
1% 
DMSO 
 2 µM SRPK2 
 1 – 100 µM OUL35  
   
E 
           
 25 µl  
10 µl 1 µM NAD+ 10 µl 
F 
50 mM 
Tris 
 150 nM PARP10 
  10 µl 150 nM ARTD10  
    
G 
            
  10 µl  
 10 µl 2 µM SRPK2  
H 
 2 µM 
SRPK2 
 5 µl 1% DMSO 
  1 – 100 µM OUL35  
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NAD+ is consumed as in the enzymatic reaction. The reaction occurs on 96-well plate in shaking 
incubator, which keeps the temperature constant overnight. The following day the reaction is 
halted by denaturing the proteins with 2 M potassium hydroxide (KOH), which also makes the 
conditions basic. Straightly after denaturing the protein, 20% acetophenone is introduced to 
solution to start a two-step reaction, which transforms the remaining NAD+ into a fluorescent 
form. The second part of the reaction occurs after incubation with 100% formic acid, which 
stabilizes the reaction. The excitation wavelength and emission wavelength were 372 and 444 
nanometers (nm), respectively. On figure 4, an overview of the reaction is presented. (Putt & 
Hergenrother, 2004; Venkannagari et al., 2013) 
 
 
 
 
 
 
Figure 4: An overview of chemical conversion of NAD+. 
 
4.4 Cell cultures 
 
To obtain Hela-, MDA-MB-231 –and MCF-7 –cells for further experiments, the cells were 
grown in an incubator with a temperature of +37 °C, CO2 levels at 95% and O2 levels at 5%. 
The cells were plated on 10 cm plates using Dulbecco’s modified eagle’s medium (DMEM; 
10% volume/volume (V/V) fetal bovine serum (FBS), 1% (V/V) penicillin/streptomycin (P/S)) 
as growing medium. The cells were observed regularly, and they were divided into several 
plates when required. The cell lines were selected according to their reported ARTD10 
expression levels. The breast cancer cell lines, MDA-MB-231 and MCF7, are suggested to 
express high amount of ARTD10, whereas HeLa cells, cervical cancer cells, are suggested to 
express only little as a compare thus serving as a negative control. (Cell atlas; Expression Atlas) 
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On table III, the overview of the PARP10 expression in the cell lines mentioned above is shown. 
The cells are arranged from highest expression levels to the lowest expression levels in 
transcripts per million (TPM) -units. The values were obtained from Cell Atlas and Expression 
Atlas. 
 
Table III: An overview of TPM values of cell lines used in the experiment. The TPM values 
were obtained from Cell Atlas and Expression Atlas, and they differed from each other greatly. 
MCF7 cell line had several TPM values in Expression Atlas, the value on table is obtained from 
a comparative proteomic analysis of cell lines. At the time, TPM values for every cell line from 
both databases was unachievable. The Expression Atlas search was commenced with 
“PARP10”, “Homo sapiens”, “HeLa”, “MDA-MB-231”, and “MCF7”. The bolded values were 
considered as expected values for the experiments. (Cell atlas; Expression Atlas) 
PARP10 expression 
Cell line Cell line type 
Organ 
(example) 
Origin 
(example) 
TPM (Cell 
Atlas/Expression 
Atlas) 
MCF7 
Breast 
adenocarcinoma 
Breast Epithelial 16.5/2 
MDA-MB-231 
Breast ductal 
adenocarcinoma 
Breast 
Mammary 
gland 
x/15 
HeLa Adenocarcinoma Cervix Epithelial 6.6/11 
 
4.5 Cell confluency experiments with IncuCyte 
 
The cell confluency experiments were done with MDA-MB-231 –and MCF7 –cells with 
IncuCyte. The IncuCyte is an incubator, which takes images of cells on clear 96-well plate in 
every two hours. The images are analyzed with IncuCyte ZOOM 2015A (IncuCyte), which 
analyses the total confluency of the cells, and thus, the viability. The obtained raw data is 
analyzed with any spreadsheet application, and the curves can be processed according to these 
values. 
19 
 
The quantity of the cells in each well of 96-well plates (Corning, 3599) were 50 000/ml, and 
the compounds used were dimethyl sulfoxide (DMSO), PARP10 inhibitor OUL35, 
topoisomerase II inhibitor Teniposide (VM-26, SML0609), potent topoisomerase I inhibitor 
Irinotecan hydrochloride (I1406), thymidylate synthase inhibitor 5-fluorouracil (5-FU) 
(F6627), anti-neoplastic ribonucleoside reductase hydroxyurea (HU) and DNA replication 
inhibitor Cytarabine (ARA-C) (C1768). (PubChem; Sigma-Aldrich) 
Furthermore, the obtained data was processed with Excel (Microsoft), calculating the averages 
and standard error of the mean (SEM) values, and the curves were drawn using GraphPad Prism 
8.0.2., and the curves were processed into their final form using CorelDRAW 2018 (Corel). On 
table IV, layout of the experiment is shown. 
 
Table IV: Layout of the cell confluency experiment. All wells had a final volume of 200 µl. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
0.1 % 
DMSO 
10 µM 
OUL35 
0.1 % 
DMSO 
0.1% 
DMSO 
0.1 % 
DMSO 
0.1% 
DMSO 
0.1 % 
DMSO 
10 µM 
OUL35 
10 µM 
OUL35 
10 µM 
OUL35 
10 µM 
OUL35 
10 µM 
OUL35 
B 
C 
D 
E 
10 µM 
Teniposide 
10 µM 
Irinotecan 
10 µM  
5-FU 
100 µM 
HU 
10 µM 
ARA-C 
10 µM 
Teniposide 
10 µM 
Irinotecan 
10 µM 
 5-FU 
100 µM 
HU 
10 µM 
ARA-C 
F 
G 
H 
 
4.6 Cell fractionation 
 
The cell treatments were performed as triplicates of all four set-ups (DMSO (control), OUL35, 
Hydroxyurea (+DMSO) and HU + OUL35), using 24 h -and 72 h time intervals. The cells were 
first counted, aim was to have 2 000 000 cells on each plate. The following day, the media was 
changed, and the compounds were added. On table V, the final concentrations of compounds 
are displayed. 
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Table V: Final concentrations of compounds on 10 cm plates. The stocks were 100% 
DMSO, 200 mM HU, and 10 mM OUL35. 
Compound Final concentration 
DMSO 0.1% 
HU 100 µM 
OUL35 10 µM 
 
The fractionation commenced with ice-cold 1x phosphate buffer serine (PBS) wash, followed 
by introduction of 500 µl of ice-cold fractionation buffer (20 mM HEPES, 10 mM KCl, 2 mM 
MgCl2, 1 mM egtazic acid (EGTA), 1 mM ethylenediaminetetraacetic acid (EDTA), distilled 
water (dH2O); added 1000x pefablock (1/5) and 1 mM TCEP just before pipetting). After the 
fractionation buffer was added on plates, the cells were scraped off, and lysate was pipetted into 
the 1.5 ml Eppendorf tube (700 µl/tube). The cells were then incubated on ice for 15 minutes. 
After incubation, cells were passed through 27 G needle ten times, and centrifuged with 
microcentrifuge (Eppendorf centrifuge 5415 C; 10 minutes, 3000 rpm, +4 °C). After first 
centrifuge run, supernatant was transferred into separate 1.5 ml Eppendorf tube (cytoplasmic 
fraction). The obtained pellet was dissolved into 500 µl of fractionation buffer followed by ten 
passes of 25 G needle, and the suspension was centrifuged as mentioned previously. 
After last centrifuging, supernatant was discarded, and the pellet was dissolved into 250 µl 
nuclear lysis buffer (tris buffer saline (TBS), 0.1% sodium dodecyl sulphate (SDS). Before 
freezing the fractions, the genome of nuclear fractions was sheared using water bath sonicator 
(Branson 3510) for approximately 10 seconds. 
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4.7 Western blot 
 
Western blot is a method, which involves protein transfer from SDS-PAGE gel on a 
nitrocellulose or polyvinylidene fluoride (PVDF) membrane with electric field. The transfer 
can be made with dry, semi-dry or wet transferring (semi-dry was used in case of four 
membranes, and wet transfer in case of rest twelve membranes). In semi-dry western blot 
transfer method, the methanol in transfer buffer was replaced with ethanol (1x tris-glycine (TG) 
–buffer (BioRad), 20% ethanol (EtOH), dH2O). After the transfer, membranes are incubated 
with blocking buffer (in this case; tris-buffered saline (TBS), 2% casein) to suppress nonspecific 
signals during imaging. The blocking is followed up by the immunostaining, which is usually 
a two-step incubation with primary antibodies and secondary antibodies. Both antibodies, 
primary and secondary, were diluted in blocking buffer. The primary antibody incubation 
occurs usually overnight, making sure as much antibodies as possible is bound to wanted 
protein. The horseradish peroxidase (HRP) labeled secondary antibodies bind to the primary 
antibodies and the enhanced chemiluminescence (ECL) provides luminescence when reacting 
with HRP and thus, visual bands. If the primary antibody is specific, only one protein band is 
visible after imaging. The imaging includes an ultraviolet (UV) exposure of blot, providing the 
luminescence mentioned previously. 
A loading control should be made for band intensity determination. The determination is made 
via comparison between the wanted protein expression and expression level of highly expressed 
protein. The intensity can be determined with programs capable to sense the band intensities 
such as Image Lab (BioRad), and the value of wanted protein is divided by the loading control 
value. Before the loading control visualization, the membrane must be stripped from previous 
antibodies. To accomplish this, the membranes are firstly treated with warm stripping buffer 
(1x stripping buffer, 0.7% β-mercaptoethanol). Once the membrane is stripped from the 
antibodies from previous imaging, the membrane is washed and re-blocked. After re-blocking, 
the membrane can be blocked with new primary antibody. 
Western blot analysis was performed to seek the amount of expressed PARP-10 in three 
different cell lines. These cell lines were HeLa, MDA-MB-231, and MCF7, from which HeLa 
had hypothetically lowest ARTD10 expression levels, MDA-MB-231 fair ARTD10 expression 
levels, and MCF7 having hypothetically the highest ARTD10 expression levels of the 
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experiment. The primary antibody used was ARTD10 antibody from Santa Cruz Biotechnology 
(5H11, unconjugated monoclonal rat IgG, 1/200 dilution) and the secondary antibody used was 
goat-anti-rat from Jackson (112-035-003, HRP conjugated polyclonal goat IgG, 1/5000 
dilution). The loading control for cytoplasmic fractions was performed with β-tubulin antibody 
from Jackson (ab21058, HRP conjugated polyclonal rabbit IgG, 1/1000 dilution), and in case 
of nuclear fractions, Histone H3 from Novus (NB500-171, unconjugated polyclonal rabbit IgG, 
1/2000 dilution) was used and as a secondary antibody, goat-anti-rabbit from Jackson (111-
035-003, HRP conjugated polyclonal goat IgG, 1/5000 dilution). The bands were visualized 
with ECL (Advansta WesternBright™).  
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5. Results and discussion 
 
5.1 Protein purification 
 
ARTD10 was purified with IMAC, heparin, AEC, and SEC, and on following images, the level 
of purity after each chromatography step is represented. This step was made to obtain as pure 
ARTD10 as possible. Overall, the purity level of ARTD10 solution was appropriate for 
biochemical analysis after SEC, and as expected, the first steps (IMAC, heparan, AEC) did not 
purify the protein solution to its final form. In the end, ARTD10 concentration of approximately 
35.90 µM (3.95 mg/ml) and yield of 2.63 mg/l was obtained. 
On figure 5, a purity check with SDS-PAGE of ARTD10 after IMAC is shown. As expected, 
impure protein solution after the first step of the purification was obtained. This image also 
includes the gels with IMAC elution, and heparan flow-through. On figure 6, the purity level 
of the protein solution containing ARTD10 after AEC run is shown alongside the 
chromatogram. According to the peaks of AEC chromatogram, fractions 2, 9, 13, and 21 were 
collected, to see whether ARTD10 is present or not. On figure 7, the SDS-PAGE check of 
ARTD10 purity after SEC run alongside chromatogram is shown. According to SEC 
chromatogram, fractions 9, 13, 17, and 21 were collected. Furthermore, fractions 12-20 were 
combined for purity check.  These fractions were chosen to see whether there is ARTD10 
present or not. The standard well was contaminated with protein samples from other wells. 
Thus, it is not shown on figure 7. 
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Figure 5: Gel images of ARTD10 purity after IMAC and heparin (three separate gels). A 
and B represents two separate gels containing IMAC samples, whereas C represents a gel with 
ARTD10 solution after heparin run. A contains the flow-through, wash with Washing Buffer 1 
and wash with Washing Buffer 2, B contains the flow-through with elution buffer, and C 
contains heparan flow-through with buffer A. The bands representing ARTD10 are marked 
with a rectangle. 
 
 
 
 
 
 
 
Figure 6: A gel image and AEC chromatogram. A represents the gel image showing level of 
ARTD10 purity after the chromatography run, and the bands representing ARTD10 are marked 
with rectangle. The bands consist of AEC run (fractions 2, 9, 13 and 21), and concentrated 
elution of AEC, as comparison for AEC elution. B represents the AEC chromatogram. 
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Figure 7: A gel image and SEC chromatogram. A represents the SDS-PAGE gel run after 
SEC run, and the bands representing ARTD10 are marked with rectangle. The gel image 
consists of Fraction 9, 13, 17, 21, and fraction combination (12-20). B represents SEC 
chromatogram for ARTD10, from which the fractions for purity check were chosen. 
 
5.2 IC50 
 
According to previous studies, the construct of ARTD has most likely an effect on the 
inhibition. To verify that whether OUL35 is equally effective against full-length ARTD10 and 
the catalytic domain or not, IC50 experiment was made. Thorsell and colleagues (2017) 
recognized that the enzymatic activity of catalytic domain of ARTD1, ARTD2, and ARTD3 is 
significantly decreased as compared to the full-length construct, whereas ARTD10 activity did 
not vary. Venkannagari and colleagues (2016) has measured the IC50 value of catalytic domain 
of ARTD10 with OUL35 as 329 nM (pIC50 ± SEM: 6.48 ± 0.04), whereas an average IC50 value 
of three experiments was 510 nM (pIC50 ± SEM: 6.29 ± 0.04). Thus, it can be concluded that 
the full-length ARTD10 inhibition with OUL35 lowers the activity at same level as catalytic 
domain, indicating there is no large differences between the constructs. On figure 8, a curve 
representing the ARTD10 activity with presence of OUL35 with different concentrations is 
shown. (Venkannagari et al., 2016; Thorsell et al., 2017)  
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Figure 8: IC50 curves. The IC50 value was 510 nM (pIC50 ± SEM: 6.29 ± 0.04). 
 
These results support the spotted inhibitory effect from cell experiments. The IC50 value of full-
length ARTD10 is close to the IC50 value obtained from a catalytic domain. There is, however, 
a small difference on these results, suggesting the other domains may have an influence on the 
catalytic activity. However, as the differences are minimal, either the full-length protein or 
catalytic fragment can be used likely in reliable IC50 measurements and ranking of the inhibiting 
compounds. (Venkannagari et al., 2016; Thorsell et al., 2017) 
 
5.3 ARTD10 localization and inhibitor effects on expression levels 
 
This experiment was conducted to detect whether OUL35 has effect on ARTD10 localization 
in cells under DNA stress. To obtain the results, the cells were treated as explained earlier in 
sections 4.6 and 4.7. On figures 9 and 10, the western blot images representing the results of 
OUL35 effects on different cell lines are shown in nucleus and cytoplasm. On figure 9, only 
the bands are shown due lack of loading control, whereas on figure 10, the images are combined 
with a graph representing the band intensity level against amount of β-tubulin. The alphabets 
A-H represent the different membranes, being in case of figure 9, nuclear fractions, and in case 
of figure 10, a comparison of amount of cytoplasmic ARTD10 after 24h and 72h. A and B 
represents the comparison of overall ARTD10 between the cell lines used in the experiment, 
C-D being comparison of amount of ARTD10 between DMSO (control), OUL35, HU and HU 
with OUL35 in HeLa cell fractions, E-F being comparison of amount of ARTD10 between 
DMSO (control), OUL35, HU and HU with OUL35 in MDA-MB-231 cells, and G-H being 
comparison of amount of ARTD10 between DMSO (control), OUL35, HU and HU with 
OUL35 in MCF7 cell fractions. The cells were treated on images A-B with 0.1% DMSO, and 
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on images C-H, with 0.1% DMSO, 10 µM OUL35, DMSO and 20 µM HU, and OUL35 and 
HU. Examples of western blot images are shown in appendix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: ARTD10 expression levels in nucleus. A and B represents the ARTD10 expression 
levels in HeLa, MDA-MB-231 -and MCF7 cell-lines with 0.1% DMSO treatment, C and D 
represents ARTD10 expression levels in nuclear fractions of HeLa cells, E and F represents 
ARTD10 expression levels in nuclear fractions of MDA-MB-231 cells, and G and H represents 
ARTD10 expression levels in nuclear fractions of MCF7 cells. All cell lines were treated for 
24h and 72h, respectively. 
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Figure 10: ARTD10 expression levels in cytoplasmic samples. A and B represents expression 
levels in HeLa, MDA-MB-231 -and MCF7 cell-lines with 0.1% DMSO treatment, C and D 
represents ARTD10 expression levels in cytoplasmic fractions of HeLa cells, E and F represents 
ARTD10 expression levels in cytoplasmic fractions of MDA-MB-231 cells, and G and H 
represents ARTD10 expression levels in cytoplasmic fractions of MCF7 cells. All cell lines 
were treated for 24 h and 72 h, respectively.1 represents the graph displaying the band intensity, 
whereas 2 represents the ARTD10-bands from western blot. 
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According to the band intensities, such as images G and H on figure 10, the ARTD10 levels in 
cytoplasm appears to decrease after 24h. Also, OUL35 appear to have no effect on cytoplasmic 
ARTD10. In the nucleus, there appear to be less ARTD10 after treating the cells with 
compounds as compared to the DMSO (control). However, the triplicates from this experiment 
are not equal (figures 9 and 10), therefore the consistency should be improved. The main 
improvements are elimination of pipetting errors and collecting equal amounts of cells from 
plates. Furthermore, because of the inappropriate secondary antibody for loading control of 
nuclear fractions, the ARTD10 level quantification in nucleus was unachievable. Thus, this 
experiment should be made again, and in case of nuclear fractions, with different antibodies. 
The used antibody was anti-H3, hence, and another antibody for this experiment could be 
against H4 histone. Alternatively, the fractions could be analyzed with protein amount 
determination before SDS-PAGE using protein concentration measuring devices such as 
NanoDrop, to have a backup, even if the loading control is insufficient. Moreover, the results 
don’t indicate HU effect in translocation of ARTD10 from cytoplasm into nucleus, hence, more 
experiments should be conducted.  
Alongside the localization results, the results show that the MDA-MB-231 cells expresses more 
ARTD10 than the other cell lines used in the experiment, as seen on images A and B (figure 
10). MCF7 cells appears to express more ARTD10 than HeLa cells despite the search result 
from Expression Atlas, and MCF7 expresses clearly less ARTD10 than MDA-MB-231 cells, 
unlike Cell Atlas informed. Therefore, the values from databases should not blindly be relied 
on. The results from the localization experiments indicates that at 24h, the treatment with 
OUL35 has no drastic effect on ARTD10 levels on cytoplasm as compared to control (DMSO 
treatment), as seen on figures C-H (figure 10). Also, HU alone appear to increase the amount 
of cytoplasmic ARTD10 slightly, indicating this compound induces ARTD10 expression, and 
according to the graphics, OUL35 seem to enhance this effect, as represented on images C1, 
D1, and E1. 
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5.4 Sensitization effect of ARTD10 inhibition 
 
To determine whether OUL35 sensitizes breast cancer cell lines (MCF7, MDA-MB-231) to 
DNA damage, the IncuCyte observation was conducted as described in section 4.5. During this 
experiment, the cells were treated with teniposide, irinotecan, 5-FU, HU, and ARA-C. OUL35 
acted as a sensitization compound, and DMSO as a control. DMSO is used broadly as a solvent 
in topological treatments as penetration increaser, cell cryopreservation, and pharmacology and 
toxicology. It has been noted to possess medical properties such as muscle relaxation, diuretics, 
anti-inflammation, vasodilation, and nerve blockade (Verheijen et al., 2019). OUL35 is used as 
a selective ARTD10 inhibitor. It binds to the NAD+ pocket of ARTD10, preventing the 
MARylation. According to the results, the single-agent effect of OUL35 had no effect on 
cellular proliferation, whereas Venkannagari and colleagues (2016) noticed this compound to 
preserve HeLa cells, via inhibiting the apoptosis due overexpression of ARTD10. It appears 
ARTD10 inhibition has a dual effect, both sensitizing to DNA damage, and protecting from 
apoptosis. (Venkannagari et al., 2016) 
Hydroxyurea (HU) is a potent teratogen with anticancer properties. It inhibits ribonucleotide 
reductase, which takes part in deoxynucleoside triphosphate (dNTP) synthesis. When dNTP 
synthesis is inhibited, DNA synthesis is prevented and the early S phase cell cycle is halted 
(Benito et al., 2007). One result from a study of Montano and colleagues (2012) showed that 1 
mM concentration decreases MDA-MB-231 cell viability approximately to 50%. In case of 
MCF7 cells, viability is proven to be decreased by HU from concentrations 10-625 µM, and to 
kill these cells effectively, concentration should be over 1 mM. (Montano et al., 2012; Shahabi 
et al., 2014).  
Teniposide is used as an anticancer drug, primarily in case of acute lymphocytic leukemia of 
children, brain tumors and lung cancer. This compound acts as an inhibitor of mitosis, by 
stabilizing topoisomerase II (Yoneda & Cross, 2010). Sánchez-Alcázar and colleagues noted 
teniposide to increase cytochrome c expression in mitochondria of MDA-MB-231 cells, 
resulting in lower oxygen intake (Sánchez-Alcázar et al., 2001).  
Irinotecan hydrochloride is used as a chemotherapeutic, which was first used as a treatment for 
colorectal cancer (CRC). It is a prodrug, which is metabolized into its active form, 7-ethyl-10-
hydroxycampothecin (SN-38), by carboxylesterase. This compound is one of the camptothecins 
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(CPTs), which targets specifically topoisomerase I. The cytotoxic effects of CPTs are specified 
for S-phase (Rasheed & Rubin, 2003; Fujita et al., 2015). 
5-fluorouracil (5-FU) is commonly used as treatment in case of CRC. The cytotoxicity of this 
compound is based on DNA damage caused via fusing into DNA, thymidylate synthase (TS) 
inhibition by 5-fluoro-2´-deoxyuridine-5´-monophosphate (FdUMP, a 5-FU metabolite) 
followed by DNA and thymidylate biosynthesis inhibition, and fusion of 5-FU into RNA 
followed by RNA processing and function alterations (Copur et al., 1995). Li and colleagues 
noted 53BP1 has a synergetic effect with 5-FU against MDA-MB-231 -and MCF7 cells (Li et 
al., 2013). It has been detected 5-FU cytotoxic effects on both MDA-MB-231 -and MCF7 cells 
are visible, if the concentration is exceeded 100 µM (Gomaa et al., 2015; Chen et al., 2017).  
Cytarabine (ARA-C) is a potent drug against acute myeloid leukemia. It inhibits the DNA 
during checkpoint of G1/S phase, and in case of some leukemic cells, prevents progression into 
S-phase (Momparler, 2013). In previous studies, both MDA-MB-231 -and MCF7 cells are 
noticed to be sensitive to this compound (Strasser et al., 2006; Li et al., 2008).  
 
5.4.1 Example specimens of visual effects of potent and ineffective compounds 
 
On figures 11 and 12, the cell viability at day 7 of the experiment are shown. Figure 11 
represents the observation of MDA-MB-231 whereas figure 12 the observation of MCF7 cells. 
On these images, cells are under conditions of DMSO, OUL35, HU with and without OUL35, 
and irinotecan with and without OUL35. The images are labeled as letters A-F, A being 0.1% 
DMSO-treated cells, B being 10 µM OUL35-treated cells, C being 100 µM HU treated cells 
with 0.1% DMSO, D being 100 µM HU with 10 µM OUL35, E being 10 µM irinotecan with 
0.1% DMSO, and F being 10 µM irinotecan with 10 µM OUL35. 
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Figure 11: MDA-MB-231 cells, day 7 of the observation. A represents MDA-MB-231 cells 
with DMSO treatment, B represents MDA-MB-231 cells with OUL35 treatment, C represents 
MDA-MB-231 cells with HU treatment, represents MDA-MB-231 cells with HU and OUL35 
treatment, E represents MDA-MB-231 cells with irinotecan treatment, and F represents MDA-
MB-231 cells with irinotecan and OUL35 treatment. 
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Figure 12: MCF7 cells, day 7 of the observation. A represents MCF7 cells with DMSO 
treatment, B represents MCF7 cells with OUL35 treatment, C represents MCF7 cells with HU 
treatment, represents MCF7 cells with HU and OUL35 treatment, E represents MCF7 cells with 
irinotecan treatment, and F represents MCF7 cells with irinotecan and OUL35 treatment. 
 
As seen on figures 11 and 12, both cell lines are undoubtedly dying under conditions of 
irinotecan, and the OUL35 barely enhance this effect, as on images E and F on both figures. As 
a comparison, DMSO, OUL35 only, and HU with and without OUL35 appears to inflict no or 
only little damage to the cells, as shown on images C and D on both figures. 
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5.4.2 Graphical representations of IncuCyte experiment 
 
On figure 13, the combined curves for IncuCyte observations can be seen. The backbone of the 
curves consists of values obtained from average confluency from three plates. The alphabets 
A-E represents the different setups. A indicates teniposide treatment, B irinotecan treatment, C 
5-FU treatment, D HU treatment, and E ARA-C treatment. Numerals 1 and 2 represents the cell 
lines, 1 indicating MDA-MB-231, whereas 2 indicates MCF7 cells.  
According to the graphs, HU kills MDA-MB-231 cells slightly more effectively than 
teniposide, whereas MCF7 cells appear to suffer as much damage as with teniposide treatment 
(figures 13A and 13D). On the last curves, the results indicate that ARA-C is almost as effective 
as irinotecan, and OUL35 enhances the cytotoxic effects on MCF7 cells (figure 13E). It appears 
that the irinotecan and ARA-C are the most potent cytotoxic compounds for the cells used in 
this experiment, as shown on figures 13B and 13E. The least cytotoxic compounds to MDA-
MB-231 -and MCF7 cells are teniposide, 5-FU and HU, as figures 13C and 13D represents. 
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Figure 13: Graphs representing the cell confluences during IncuCyte observation. A 
represents the Teniposide-treated cells, B represents the Irinotecan treatment, C represents 5-
FU treatment on cells, D represents HU treatment on cells, and E represents ARA-C treatment 
on cells. The numeral 1 represents MDA-MB-231 cells and 2 represents MCF7 cells. 
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5.4.3 The compounds with the least cytotoxic effect on the cells 
 
According to the results, HU alone has a slight impact on MDA-MB-231 cells, and OUL35 
appear to increase this effect, as represented on curve D1 (figure 13). Whereas in case of MCF7 
cells this compound expressed only a little cytotoxic activity, and OUL35 had only a slight 
effect on cytotoxicity of this compound, as shown on curve D2 (figure 13). Teniposide appears 
to have only a slight cytotoxic impact on MDA-MB-231 -and MCF7 cells. At the used 
concentration, OUL35 appeared to protect MDA-MB-231 cells, possibly due inhibition of 
ARTD10-induced apoptosis, whereas showing a slight impact on MCF7 cells (Venkannagari 
et al., 2016). Hence, it can be concluded that OUL35 is not the best synergetic compound for 
teniposide. These events can be seen on curves A1 and A2 (figure 13). The last least effective 
compound to be analyzed is 5-FU. According to the results, MDA-MB-231 cell viability appear 
to decrease a little, and OUL35 appear to show a slight cell preservation, as shown on curve C1 
(figure 13). Furthermore, in case of MCF7 cells, this compound has no effect, and it appears 
the OUL35 increase the cell viability slightly, as illustrated on the curve C2 (figure 13).  
 
5.4.4 The compounds with the most cytotoxic effect on the cells 
 
Native MDA-MB-231 -and MCF7 cells are detected to be sensitive to SN-38 (Jandu et al., 
2016), and according to the obtained results, this compound appears to have a clear cytotoxic 
effect on these cell lines. However, the cytotoxic effect of this compound was excessive, 
indicating lower concentration should have been used. The OUL35 was not enhancing the 
cytotoxic effects significantly, and if the concentration is increased, irinotecan is so toxic the 
sensitization results are difficult to verify. The powerful cytotoxic effects of irinotecan are 
visualized on curves B1 and B2 (figure 13). Alongside irinotecan, ARA-C was most effective 
compound. OUL35 had only a slight effect on the cytotoxicity, decreasing viability of MDA-
MB-231, as visualized on curve E1 (figure 13), and increasing MCF7 viability a little, as curve 
E2 (figure 13) indicates. 
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5.4.5 Statistical significance of the cell viability results 
 
To determine the statistical significance of the cell confluency curves from IncuCyte 
experiment, a one-way analysis of variance (ANOVA) test was conducted, and the graphics 
obtained from this test is shown on figure 14. The values represented as a graph are averages 
of last time point and SEM value, and above each graph, statistical significance is shown (ns 
stands for not significant, ** stands for p < 0.005, *** stands for p < 0.001, and **** stands for 
p < 0.0001). According to the obtained results, it can be indicated that OUL35 does not affect 
significantly on the cellular proliferation on neither MDA-MB-231 nor MCF7 cells. Also, the 
OUL35 does not enhance the effect of any compound significantly. Teniposide has only a slight 
cytotoxic effect on both cell lines, indicating the too low concentration. In the stark contrast, 
irinotecan kills cells too effectively, leaving only approximately 20% of the cells alive at the 
end of the observation, indicating too high concentration used in the experiment. 5-FU was the 
least cytotoxic compound used during the experiment, suggesting too low concentration was 
used. HU in the other hand was killing roughly half of the cells during the observation period, 
having less effect on the MCF7 cells. Alongside irinotecan, ARA-C kills cells from both cell 
lines effectively, indicating the too high concentration in the experiment. 
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Figure 14: A one-way ANOVA test. Alphabets A-D represents the MDA-MB-231 -and MCF7 
cells with different treatments. A and B represents MDA-MB-231 cells and MCF7 cells with 
teniposide treatment, whereas C and D represents MDA-MB-231 cells and MCF7 cells with 
irinotecan treatment, E and F represents MDA-MB-231 cells and MCF7 cells with 5-FU 
treatment, G and H represents MDA-MB-231 cells and MCF7 cells with HU treatment, and I 
and J represents MDA-MB-231 cells and MCF7 cells with ARA-C treatments. 
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5.4.6 Summary of the cell sensitization 
 
As a summary, according to the one-way ANOVA test, the only compounds with statistically 
significant results were irinotecan, as proven on graphs C and D and ARA-C, as shown on 
graphs I and J (figure 14). According to these results, it can be concluded that these compounds 
had most likely too high concentrations. The OUL35 did not enhance significantly the cytotoxic 
effects of any compounds used during the experiment, suggesting there should be more cell 
lines to be tested. The least effective compound was 5-FU, which had no effect on neither cell 
lines, suggesting the used concentration was too low. This can be seen on graphs C1 and C2 
(figure13), and graphs E and F (figure 14). 
 
5.5 Future and the next steps 
 
In the future, the cell confluency studies could be made with broader variety of cell lines 
alongside different compounds, such as cisplatin, irinotecan and ARA-C with lower 
concentrations, 5-FU and teniposide with higher concentration, and doxorubicin. These 
compounds should be tested alongside different ARTD10 inhibitors with varying 
concentrations, to seek the most appropriate combinations. Another appropriate option is to use 
immunostaining to detect the localization more efficiently, which was planned but not 
established due to challenges on finding appropriate antibody within already tight time 
schedule. Furthermore, the DNA-damaging agent/PARPi combinations should be tested with 
native cells alongside cancer cells, such as MDA-MB-231, to seek the concentrations killing 
only the cancer cells. The mechanism changing the ARTD10 levels after treatment of different 
DNA-damaging agents, such as irinotecan with and without OUL35, could be quantified using 
western blot assay. 
40 
 
6. Conclusions 
 
According to the results obtained from this experiment, it can be concluded the full-length 
ARTD10 inhibition does not vary from the catalytic domain, OUL35 may enhance the effect 
of DNA damaging agents, and there is a possibility that HU might have an influence on nuclear 
translocation of ARTD10. However, in case of sensitization -and translocation studies, the 
effects of these compounds are cell line dependent, and the statistical significance is not 
occurring with successive rate. Thus, the obtained results warrant larger studies using a wider 
range of breast cancer cell lines alongside MDA-MB-231 -and MCF7 cells, such as T-47D, and 
other DNA damaging agents, such as cisplatin, alongside OUL35. Furthermore, the discovery 
of ARTD10 subtypes and sensitizing mutations in cancer could lead to insights to be utilized in 
clinical studies. 
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Appendix  
 
 
 
 
 
 
 
Examples of western blot membranes (MDA-MB-231 cells). A represents the western blot 
membrane with ARTD10 from cytoplasmic fraction merged with loading control image. For 
this image, 180.0 second exposure time was used in case of ARTD10 bands, and in case of β-
tubulin bands, 2.5 seconds. B represents a western blot membrane containing nuclear fractions 
merged with loading control image. On this image, 600.0 second exposure was used both in 
case of ARTD10 and non-detectable H3 bands. All fractions of this image are obtained after 
24h of compound administrations. The bands of interest are marked with rectangle, and the 
names of proteins are displayed next to the membrane images. 
